Literature DB >> 12036883

Effect of rapamycin on the cyclosporin A-resistant CD28-mediated costimulatory pathway.

Paritosh Ghosh1, Meredith A Buchholz, Shingo Yano, Dennis Taub, Dan L Longo.   

Abstract

The consequences of T-cell activation depend exclusively on costimulation during antigen-T-cell receptor interaction. Interaction between the T-cell coreceptor CD28 and its ligand B7 during antigen-antigen receptor engagement results in full activation of T cells, the outcomes of which are proliferation and effector functions. The ability of CD28 to costimulate the production of interleukin-2 (IL-2) explains the importance of this costimulation. The signaling event mediated by CD28 engagement has been proposed to have 2 components: one is sensitive to the immunosuppressive drug cyclosporin A (CsA), and the other one is CsA-resistant. In this report, we demonstrate that the CsA-resistant pathway is sensitive to the immunosuppressive drug rapamycin. Treatment with rapamycin blocked IL-2 production after activation of human peripheral blood T cells with phorbol ester (PMA) and anti-CD28 (CsA-resistant pathway), whereas this drug did not have any effect on PMA plus ionomycin stimulation (CsA-sensitive pathway). The inhibitory effect of rapamycin was on messenger RNA stability and translation, rather than on IL-2 transcription or protein turnover.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12036883     DOI: 10.1182/blood-2001-11-0062

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

1.  Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study.

Authors:  Phillip Scheinberg; Colin O Wu; Olga Nunez; Priscila Scheinberg; Carol Boss; Elaine M Sloand; Neal S Young
Journal:  Haematologica       Date:  2009-01-30       Impact factor: 9.941

2.  Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease.

Authors:  David C Fajgenbaum; Ruth-Anne Langan; Alberto Sada Japp; Helen L Partridge; Sheila K Pierson; Amrit Singh; Daniel J Arenas; Jason R Ruth; Christopher S Nabel; Katie Stone; Mariko Okumura; Anthony Schwarer; Fábio Freire Jose; Nelson Hamerschlak; Gerald B Wertheim; Michael B Jordan; Adam D Cohen; Vera Krymskaya; Arthur Rubenstein; Michael R Betts; Taku Kambayashi; Frits van Rhee; Thomas S Uldrick
Journal:  J Clin Invest       Date:  2019-08-13       Impact factor: 14.808

3.  CD28-mediated regulation of multiple myeloma cell proliferation and survival.

Authors:  Nizar J Bahlis; Anne M King; Despina Kolonias; Louise M Carlson; Hong Yu Liu; Mohamad A Hussein; Howard R Terebelo; Gerald E Byrne; Bruce L Levine; Lawrence H Boise; Kelvin P Lee
Journal:  Blood       Date:  2007-02-20       Impact factor: 22.113

4.  CZ415, a Highly Selective mTOR Inhibitor Showing in Vivo Efficacy in a Collagen Induced Arthritis Model.

Authors:  Andrew D Cansfield; Tammy Ladduwahetty; Mihiro Sunose; Katie Ellard; Rosemary Lynch; Anthea L Newton; Ann Lewis; Gavin Bennett; Nico Zinn; Douglas W Thomson; Anne J Rüger; John T Feutrill; Oliver Rausch; Alan P Watt; Giovanna Bergamini
Journal:  ACS Med Chem Lett       Date:  2016-06-10       Impact factor: 4.345

5.  The transfer of adaptive immunity to CMV during hematopoietic stem cell transplantation is dependent on the specificity and phenotype of CMV-specific T cells in the donor.

Authors:  Phillip Scheinberg; Jan J Melenhorst; Jason M Brenchley; Brenna J Hill; Nancy F Hensel; Pratip K Chattopadhyay; Mario Roederer; Louis J Picker; David A Price; A John Barrett; Daniel C Douek
Journal:  Blood       Date:  2009-09-23       Impact factor: 22.113

6.  Successful sirolimus therapy of an aplastic anemia patient with chronic kidney disease: A case report.

Authors:  Haiyue Niu; Weiwei Qi; Yihao Wang; Limin Xing; Rong Fu; Zonghong Shao; Huaquan Wang
Journal:  Medicine (Baltimore)       Date:  2020-06-05       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.